Levetiracetam and Gleevec drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Levetiracetam (levetiracetam) and Gleevec (imatinib mesylate). Common drug interactions include death among females and convulsion among males.

The phase IV clinical study analyzes what interactions people have when they take Levetiracetam and Gleevec. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Levetiracetam?

Levetiracetam has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 75,292 Levetiracetam users. Check the latest studies of Levetiracetam.

What is Gleevec?

Gleevec has active ingredients of imatinib mesylate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 35,415 Gleevec users. Check the latest studies of Gleevec.

On Aug, 08, 2026

16 people who take Levetiracetam and Gleevec together, and have interactions are studied.

Levetiracetam and Gleevec drug interactions.

What are the common drug interactions of Levetiracetam and Gleevec, by gender? *:

female:

Death
Cardiac disorder
Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
Dyspnoea (difficult or laboured respiration)
Encephalomalacia (localized softening of the brain substance, due to haemorrhage or inflammation)
Insomnia (sleeplessness)
Lactic acidosis (low ph in body tissues)
Liver disorder (liver diseases)
Neoplasm (tumour)
Pericardial effusion (fluid around the heart)

male:

Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
Death
Muscle spasms (muscle contraction)
Musculoskeletal discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves)
Neoplasm malignant (cancer tumour)
Neoplasm progression (growth of tumour)
Pain in extremity
Pyrexia (fever)
Vomiting
Anaemia (lack of blood)

What are the common drug interactions of Levetiracetam and Gleevec, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Death

50-59:

Glossodynia (a burning or painful sensation in the tongue)
Leukopenia (less number of white blood cells in blood)
Malignant neoplasm progression (cancer tumour came back)
Thrombocytopenia (decrease of platelets in blood)
Anaemia (lack of blood)
Dysgeusia (disorder of the sense of taste)

60+:

Death
Drug ineffective
Dyspnoea (difficult or laboured respiration)
Lactic acidosis (low ph in body tissues)
Leukaemia recurrent (repeat cancer of bone marrow or blood cells)
Pleural effusion (water on the lungs)
Renal failure acute (rapid kidney dysfunction)
White blood cell count decreased

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 3 people, 18.75%
Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 2 people, 12.50%
Spindle Cell Sarcoma (a type of connective tissue cancer in which the cells): 1 person, 6.25%
Multiple Myeloma (cancer of the plasma cells): 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%
Hemiplegia (paralysis of one side of the body): 1 person, 6.25%
Glioblastoma Multiforme (most common and deadliest of malignant primary brain tumours in adults): 1 person, 6.25%
Gastrointestinal Stromal Tumor: 1 person, 6.25%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Levetiracetam and Gleevec?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously